Literature DB >> 33538613

Eugenol improves tissue damage and oxidative stress in adult female rats after ovarian torsion/detorsion.

Bita Barghi1,2, Majid Shokoohi1,2, Amir Afshin Khaki1,3, Arash Khaki1, Maryam Moghimian4, Malihe Soltani4.   

Abstract

The current study was designed to investigate the effect of eugenol on histopathological changes and oxidative stress caused by torsion/detorsion in the ovary of adult female rats. In this study, forty-eight female Wistar rats were classified into six groups; Sham and 2 healthy group receiving 30, 60 mg/kg eugenol; ovarian torsion/detorsion; and 2 experimental groups receiving 30, 60 mg/kg eugenol. After ten days, the plasma levels of oestrogen, testosterone, and some oxidative stress markers were assessed. also, the histomorphometric study was performed. A marked degenerative changes in the TD group was observed (p < .001). The oestrogen, GPX, and SOD levels were remarkably declined in the G2 group, while they were reversed to the baseline values in groups receiving eugenol. The concentration of malondialdehyde (MDA) was remarkably increased during the ischaemia (p < .001). The treatment with eugenol significantly diminished MDA levels in different groups (p < .001). Our finding indicated that eugenol could protect the ovarian tissue against oxidative stress and tissue injury induced by torsion/detorsion.IMPACT STATEMENTWhat is already known about this subject? Ovarian torsion is one of the commonest gynecological emergencies in all age groups of the female gender. Timely diagnosis and management of ovarian torsion are crucial, especially for women of reproductive age. Detorsion is one of the interventions used for the prevention of ovarian tissue damage. Ovarian ischaemia/reperfusion is a pathophysiological condition in which decreased blood flow, and oxygen deficiency (ischaemia) are observed in ovarian tissues as a result of ovarian torsion. Following torsion, the inflammatory response induced by detorsion (reperfusion) leads to vascular endothelial cell apoptosis and microcirculation abnormalities, which are responsible for the cause of ovarian tissue damage.What do the results of this study add? This study found that eugenol, an antioxidant and anti-inflammatory agent, could be used experimentally to diminish the I/R damage in the ovary through the attenuation of detrimental histological events, decreasing the serum level of MDA and testosterone, and increasing the level of SOD and GPX enzymes. To date, there is no report on the application of eugenol for diminishing T/D-induced oxidative stress in the ovary.What are the implications of these findings for clinical practice? Eugenol has been shown to possess therapeutic properties in patients with ovarian torsion. Further clinical studies are necessary to prove the beneficial effect of eugenol on the prevention of I/R-induced ovarian damage.

Entities:  

Keywords:  Torsion; eugenol; ovary; oxidative stress; tissue injury

Year:  2021        PMID: 33538613     DOI: 10.1080/01443615.2020.1816938

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  3 in total

1.  Therapeutic Effects of Eugenol in Polycystic Ovarian Rats Induced by Estradiol Valerate: A Histopathological and A Biochemical Study.

Authors:  Zahra Kokabiyan; Parichehreh Yaghmaei; Seyed Behnamedin Jameie; Zahra Hajebrahimi
Journal:  Int J Fertil Steril       Date:  2022-08-21

2.  The protective effect of cilostazol on experimental ischemia/reperfusion injury in rats ovaries on in vitro fertilization outcomes.

Authors:  Özcan Budak; Mehmet Süha Bostancı; Osman Köse; Hüseyin Çakıroğlu; Özkan Durmaz; Erdem Çokluk
Journal:  Turk J Obstet Gynecol       Date:  2022-09-23

3.  Protective Effect of Minocycline on Bax and Bcl-2 Gene Expression, Histological Damages and Oxidative Stress Induced by Ovarian Torsion in Adult Rats.

Authors:  Mohammad Khaje Roshanaee; Seyed Hosein Abtahi-Eivary; Majid Shokoohi; Masoumeh Fani; Azamsadat Mahmoudian; Maryam Moghimian
Journal:  Int J Fertil Steril       Date:  2022-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.